Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pep-3 is a synthetic homo-dimer peptide derived from the hexapeptide FCIGRL-NH2 (Pep-1), which is a fragment of the *Vibrio cholerae* Zonula occludens toxin (ZOT). Developed through a collaboration between Chung-Ang University and the University of Maryland, Pep-3 acts as a tight junction modulator designed to enhance the oral delivery of drugs with poor membrane permeability. It functions by interacting with the zonulin receptor on the intestinal epithelium, triggering a signaling cascade that leads to the reversible opening of intercellular tight junctions. This mechanism increases paracellular permeability, thereby significantly enhancing the oral absorption and bioavailability of therapeutic agents such as Cyclosporin A and Doxorubicin. Pep-3 is primarily investigated as a pharmaceutical excipient or absorption enhancer for oral drug delivery systems.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pep-3.